Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging

被引：67
|
作者：
Baumann, Tobias [1 ]
Rottenburger, Christof [2 ,3 ]
Nicolas, Guillaume [2 ,4 ]
Wild, Damian [2 ,3 ]
机构：
[1] Univ Basel Hosp, Clin Radiol & Nucl Med, Radiol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Clin Radiol & Nucl Med, Nucl Med, CH-4031 Basel, Switzerland
[3] Univ Basel Hosp, Ctr Neuroendocrine & Endocrine Tumors, Nucl Med, CH-4031 Basel, Switzerland
[4] Royal Free Hosp, Neuroendocrine Tumour Unit, Nucl Med, Pond St, London NW3 2QG, England
来源：
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2016年 / 30卷 / 01期
关键词：
GEP NET; gastroenteropancreatic neuroendocrine tumour; somatostatin receptor imaging; SRS; glucagon-like peptide-1 receptor imaging; PET/CT; POSITRON-EMISSION-TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; ENETS CONSENSUS GUIDELINES; GLUCAGON-LIKE PEPTIDE-1; SMALL-BOWEL NEOPLASMS; PREOPERATIVE LOCALIZATION; GA-68-DOTATATE PET/CT; LIVER METASTASES; CARCINOID-TUMORS; IN-VITRO;
D O I：
10.1016/j.beem.2016.01.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Detection of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and monitoring of treatment response relies mainly on morphological imaging such as computed tomography (CT) and magnetic resonance imaging (MRI). Molecular imaging techniques also in combination with CT (hybrid imaging) greatly benefit patient management, including better localization of occult tumours and better staging. Somatostatin receptor scintigraphy (SRS) and somatostatin receptor (SSTR) positron emission tomography (PET) play a central role in the diagnostic work-up of patients with well differentiated GEP-NETS. SSTR PET/CT is superior to SRS and should be used whenever available. F-18-DOPA and F-18-FDG PET/CT is inferior to SSTR PET/CT at least in patients with well-differentiated GEP-NETs. Both SSTR PET/CT and SRS have limitations, such as relatively low detection rate of benign insulinomas, poorly differentiated GEP-NETS and liver metastases. New innovations such as SSTR PET/MRI, radiolabelled SSTR antagonists and glucagon-like peptide-1 receptor (GLP-1R) agonists might further improve imaging of GEP-NETS. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：45 / 57
页数：13
相关论文
共 50 条
  • [1] Expression of Target Molecules in Japanese Gastroenteropancreatic Neuroendocrine Tumours (GEP-NET) Patients
    Kasajima, A.
    Yazdanikivi, S.
    Sasano, H.
    [J]. JOURNAL OF PATHOLOGY, 2012, 228 : S36 - S36
  • [2] The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP-NET)
    Kanakis, George
    Kamp, Kimberly
    Tsiveriotis, Konstantinos
    Feelders, Richard A.
    Zormpala, Alexandra
    de Herder, Wouter W.
    Kaltsas, Gregory
    [J]. CLINICAL ENDOCRINOLOGY, 2013, 78 (06) : 950 - 956
  • [3] Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET)
    Goretzki, P. E.
    Starke, A.
    Akca, A.
    Lammers, B. J.
    [J]. INTERNIST, 2012, 53 (02): : 152 - 160
  • [4] Current diagnostics and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NET)
    Laubner, K.
    Brass, V.
    Weber, W.
    Seufert, J.
    [J]. ONKOLOGE, 2013, 19 (03): : 218 - +
  • [5] Prognostic Role of Smoking in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
    Pons, F.
    Mar, I.
    Galego, R.
    Luque, A.
    Gonzalez, N.
    Martinez, A.
    Guix, M.
    Montagut, C.
    [J]. NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 236 - 237
  • [6] Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET) [Chirurgie neuroendokriner tumoren des gastroenteropankreatischen systems (GEP-NET)]
    Goretzki P.E.
    Starke A.
    Akca A.
    Lammers B.J.
    [J]. Der Internist, 2012, 53 (2): : 152 - 160
  • [7] Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness
    Barrea, Luigi
    Altieri, Barbara
    Muscogiuri, Giovanna
    Laudisio, Daniela
    Annunziata, Giuseppe
    Colao, Annamaria
    Faggiano, Antongiulio
    Savastano, Silvia
    [J]. NUTRIENTS, 2018, 10 (12):
  • [8] Reduced efficacy of repeated peptide receptor radionuclide therapy (PRRT) in progressive gastroenteropancreatic neuroendocrine tumours (GEP-NET)?
    Schnurr, J.
    Reimold, M.
    Dittmann, H.
    Kupferschlaeger, J.
    Bares, R.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S396 - S396
  • [9] Colorectal Neuroendocrine Tumors of the Gastroenteropancreatic Tract (GEP-NET) - Minimal Invasive Surgery
    Szybinski, P.
    Klek, S.
    Hubalewska-Dydejczyk, A.
    Richter, P.
    Kulig, J.
    [J]. NEUROENDOCRINOLOGY, 2009, 90 (01) : 137 - 137
  • [10] Current diagnostics and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NET) [Aktuelle Diagnostik und Therapie von gastroenteropankreatischen neuroendokrinen Tumoren (GEP-NET)]
    Laubner K.
    Brass V.
    Weber W.
    Seufert J.
    [J]. Der Onkologe, 2013, 19 (3): : 218 - 223
12345